• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·AARTIIND.NS
Share

Aarti Industries Limited Stocks

₹ 483.05Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 1.84B

₹ 483.05
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Somewhat favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aarti Industries Limited, established in 1984 and headquartered in Mumbai, India, is a prominent manufacturer and supplier of both specialty chemicals and pharmaceutical products. The company's chemical division produces a wide array of compounds including dichlorobenzene, various nitro-chloro and nitro-benzene derivatives, nitro-toluenes, and sulfur, along with other organic and inorganic substances. These crucial materials serve as intermediates for a diverse range of sectors such as agrochemicals, pharmaceuticals, polymer and fuel additives, fast-moving consumer goods (FMCG), dyes, pigments, paints, printing inks, rubber chemicals, and resins. In the pharmaceutical sphere, Aarti Industries develops active pharmaceutical ingredients (APIs) utilized in medications for conditions like hypertension, asthma, cancer, thalassemia, pain relief, ophthalmic disorders, and central nervous system agents, as well as skincare and decongestant products. They also supply pharmaceutical intermediates and a selection of xanthine derivatives, prominently featuring caffeine anhydrous, theophylline, and related compounds. Beyond its manufacturing capabilities, Aarti Industries provides contract manufacturing and research services. The company maintains a significant global presence, exporting its products to approximately 60 countries across North America, Europe, China, Japan, and other international regions.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of AARTIIND.NS is 515 and suggests 6.3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommen

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 20:22

Morgan Stanley's profits soared thanks to SpaceX's IPO and revenue from stock trading

15.07.2026 19:54

Sales at Cartier's parent company were twice as strong as expected. This bolstered the luxury market

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Chip test maker Aehr extending gains after earnings and revenue beats, upbeat outlook

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026